NLRP3 and cryopyrin-associated periodic syndrome: These were prompted by the clinical observation that up to 50% of CAPS patients with identical clinical features and response to anti-IL-1 treatment, show no mutation in NLRP3 by conventional DNA sequencing, suggesting the presence of either genetic heterogeneity, or low levels of somatic NLRP3 mutations (2, 6, 7).